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Abstract
Background: There is lack of consensus concerning the best screening strategy for gestational diabetes (GDM).
The aim of our survey was therefore to investigate attitudes and practices of all obstetrical centers in the northern
part of Belgium regarding screening for pregestational diabetes in early pregnancy and screening for GDM. We also
aimed to identify the penetrance of the ‘International Association of Diabetes in Pregnancy Study Groups’ (IADPSG)
screening strategy for GDM.
Methods: The survey was conducted from May 2012 till January 2013. The survey was distributed to every
obstetrical center in the northern part of Belgium by email and/or mail with reminders by phone and personal
contact.
Results: From the 65 obstetrical centers, 69% responded. Of all centers, 27% had a structured database on the
number of women with GDM. Of all centers, 82% screened for pregestational diabetes in early pregnancy and 56%
of centers screened for GDM before 24 weeks. Screening before 24 weeks was mostly based on risk factors.
Screening for GDM after 24 weeks, was done universally in 87% of centers. The mean estimated prevalence of GDM
was 7 ± 5%. The most commonly used screening strategy was a two-step approach with a glucose challenge test
(GCT) and 100 g oral glucose tolerance test (OGTT), used by 56% of centers, with 23 centers using the Carpenter &
Coustan criteria. The 75 g OGTT with the IADPSG criteria was used by 33% of centers but 4 of these centers still
used a GCT before proceeding to the full OGTT.
Conclusions: This survey demonstrates that in the northern part of Belgium, there still is a large variation in
screening strategy for pregestational diabetes in early pregnancy and GDM. Only 25% of centers have already
implemented the one-step IADPSG screening strategy.
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Background
Besides the worldwide increase of type 2 diabetes (T2DM)
in younger adults, the maternal age at first pregnancy also
increases in the western world. The timely detection of
dysglycemia very early in pregnancy is therefore essential
as these women have an increased risk for congenital
anomalies [1]. The timely detection of gestational diabetes
(GDM) is important since the risk for fetal overgrowth
and the risk for the development of T2DM postpartum
[2,3]. The ‘International Association of Diabetes and Preg-
nancy Study Groups’ (IADPSG) consensus recommends
now an universal screening with the 2-h 75 g oral glucose
tolerance test (OGTT) from 24-28 weeks of gestation
using more stringent diagnostic criteria. Moreover, one
abnormal value is now enough for the diagnosis of GDM
[4]. Internationally there still is a lot of controversy
concerning the IADPSG recommendation for screen-
ing for GDM. In most populations, the implementation
of the IADPSG screening strategy will probably lead to
an important increase in the number of women labeled
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and treated as GDM. The American Diabetes Association
(ADA) has adopted the IADPSG recommendation since
December 2010, while the American College of Obste-
tricians and Gynecologists advises to continue with the
two-step screening strategy (universal screening with a
50 g glucose challenge test (GCT), followed by a 3-h
100 g OGTT only when the GCT is abnormal) [5,6]. In
March 2013 an independent expert panel, appointed by
the National Institute of Health, recommended that the
two-step approach be continued [7]. The panel is par-
ticularly concerned that the adoption of the IADPSG
criteria would increase the prevalence of GDM, and the
corresponding costs and interventions, without clear
demonstration of improvements in the most clinically
important health and patient-centered outcomes.
The discrepancy in recommendations is also apparent
in Belgium. In 2012 a Flemish consensus between endo-
crinologists, obstetricians and primary care physicians
decided that at this moment there is not enough evidence
to already implement the IADPSG screening strategy for
GDM and therefore recommended to continue with the
two-step screening strategy [8]. In contrast, a recent con-
sensus of ‘le Groupement des Gynécologues Obstétriciens
de Langue Française de Belgique’ was to adopt the pro-
posed IADPSG screening strategy for GDM [9].
Due to the lack of consensus on the best screening strat-
egy for GDM both internationally and nationally, the aim
of our survey was to investigate attitudes and practices of
all obstetrical centers in the northern part of Belgium
regarding screening for pregestational diabetes in early
pregnancy and screening for GDM. We also aimed to
identify the penetrance of the IADPSG screening strategy
for GDM.
Methods
An anonymous survey was designed to evaluate attitudes
and practices concerning screening for pregestational
diabetes in early pregnancy and screening for GDM
[Additional file 1]. The current study was in compliance
with the Helsinki Declaration.
The initial segment of the survey included specific ques-
tions about the general characteristics of the obstetrical
center and practice details. The next segment surveyed
provider attitudes on screening for GDM. The following
questions concerned the information included in the
protocol on GDM, if and how women were screened for
pregestational diabetes at first prenatal visit and how
screening was performed for GDM before and after 24
weeks of pregnancy. Providers could indicate that they used
more than one type of screening test if necessary. The
ultimate segment dealt with questions on the follow-up
strategy at delivery and postpartum to screen for T2DM.
The survey was conducted from May 2012 till January
2013, before the publication of the Flemish consensus
on screening for GDM. The survey was distributed to
obstetricians at conferences in the northern part of
Belgium (Flanders) or distributed to every obstetrical cen-
ter by email and/or mail. If the survey was not returned
within two months, obstetricians were reminded by phone
and/or personal contact. There are 65 obstetrical centers
in Flanders. The aim was to obtain one survey for every
obstetrical center.
The background prevalence of T2DM in Belgium is
7.0% compared to a mean prevalence of T2DM in Europe
of 8.3% [10]. Belgium has a population of nearly 11 million
of which 12% are from an ethnic minority background. 6.3
million of all Belgians live in Flanders. In the general adult
population 28% of women are overweight and 13% are
obese [11]. At the start of this century, Flanders had the
lowest rate of mothers aged 35 or more (10.9%) and one
of the lowest rates of teenage pregnancies (2.2%) among
16 regions in Western Europe [12].
Statistical analyses were performed using SPSS 19.0.
Continuous variables (normally distributed) are expressed
as mean (SD) or expressed as median if not normally dis-
tributed. Non categorical data expressed as percentage. To
compare variables between the different groups independ-
ent samples T-tests was used for normally distributed con-
tinuous variables and chi-squared tests for categorical
variables.
Results
Of all the 65 centers who received the survey, 45 completed
the survey, leading to a response rate of 69%. Responders
included 42 obstetricians and 3 endocrinologists. The
provinces Limburg, Flemish Brabant and East Flanders
had the highest response rate (resp. 88%, 71% and 69%),
followed by the province of West Flanders (60%) and
Antwerp (55%).
General characteristics
Of all responders, 7% worked in an university hospital,
27% worked in a non-university training hospital and
66% worked in a community based hospital. The mean
number of obstetricians per center was 6 (range 3-16).
The median number of deliveries per year per center
was 900 (range 400-2700). Of all centers, 27% (12) had a
database with the number of GDM women registered.
The estimated mean prevalence of GDM was 7 ± 5% but
with a very large variation (1-20%).
Attitudes of providers
All responders but one believed that it was beneficial to
screen for GDM. Moreover, a very large majority (91%
of responders) considered that screening for GDM was
well organized in their center. Only four responders con-
sidered that screening for GDM was not well organized in
their center due to the absence of a protocol (1), an
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incomplete protocol (2) or logistical problems (1). Of all
responders, 38% (17) considered that the estimated risk
for women with previous GDM to develop T2DM in
the next 10 years after the index pregnancy, is lower
than 30%.
Protocol for GDM
Of all centers, 73% (33) had a written protocol regarding
the policy for GDM. Information on screening for preg-
estational diabetes at first prenatal visit was present in
33% (15) of centers and information on the obstetrical
follow up was present in 44% (20) of centers. Informa-
tion on the delivery modalities was available in 56% (25)
of centers and information on the follow-up strategy to
screen for diabetes after delivery was present in 51% (23)
of centers. In all centers both obstetricians and endocri-
nologists were involved in the development of the proto-
col. Pediatricians were involved in the development of the
protocol in 38% (17) of centers, primary care physicians in
only 7% (3) of centers, midwifes in 33% (15) of centers,
diabetes nurses in 56% (25) of centers and dieticians in
47% (21) of centers.
Screening for pregestational diabetes in early pregnancy
Of all centers, 82% (37) regularly screened for pregesta-
tional diabetes in early pregnancy. A risk profile was
assessed by 46% (17) of centers before a screening test
was used. The most commonly used screening tests were
the measurement of a fasting plasma glucose (FPG)
(35%) or a random glycaemia (35%) [Table 1]. The esti-
mated number of women screened for pregestational
diabetes in early pregnancy was 65% (± 31%) but with a
very wide variation between centers (5-99%). The esti-
mated number of women who attended a preconceptional
clinic was 21% (± 22%).
Screening for GDM before 24 weeks of pregnancy
Of all centers, 56% (25) screened for GDM before 24
weeks of pregnancy. The estimated number of women
screened for GDM before 24 weeks of pregnancy was 30%
(± 33%). Screening based on risk factors was performed by
67% (16) of centers. The most common used risk factors
to screen for GDM were a family history of diabetes
(75%), a history of GDM (71%), being overweight or obese
(68%), a history of a macrosomic baby (29%) and a per-
sonal history of PCOS (14%). The most common used
screening tests were a GCT with a threshold ≥ 140 mg/dl
(40%), a FPG (32%), a random glycaemia (28%) and a one-
step screening approach with a 75g OGTT (24%) [Table 1].
In more than half of the centers, providers indicated that
different screening tests could be used. When a 75 g
OGTT was used, the most common diagnostic criteria
used were the IADPSG criteria (28%) [Table 2]. Of the 7
centers who used the IADPSG criteria, 6 centers did this
in a one-step approach. When the 100 g OGTT was
used, the most common diagnostic criteria used were
the Carpenter & Coustan criteria (48%). Three of the
12 centers who used the Carpenter & Coustan criteria
with the 100 g OGTT, did this as a one-step approach
without GCT.
Screening for GDM ≥ 24 weeks of pregnancy
All centers screened for GDM ≥ 24 weeks of pregnancy
and 87% (39) screened universally for GDM. Screening for
GDM was mostly performed between 24 weeks (range 20-
28) and 29 weeks (range 26-34). The most common used
screening tests were a GCT with a threshold ≥ 140 mg/dl
(64%), followed by a one-step approach with the 75 g
OGTT (27%) and a GCT with a threshold ≥ 130mg/dl
(16%) [Table 1]. The most commonly used screening
strategy was a two-step approach with a GCT and 100 g
OGTT, used by 56% of centers (25). The Carpenter &
Table 1 An overview of the screening tests used to screen for pregestational diabetes in early pregnancy, for GDM
before 24 weeks of pregnancy and for GDM ≥ 24 weeks of pregnancy
Screening tests used Pregestational diabetes (n = 37) GDM < 24 weeks (n = 25) GDM ≥ 24 weeks (n = 45)
FPG 35% (13) 32% (8) 0
HbA1c 14% (5) 4% (1) 2% (1)
Random glycaemia 35% (13) 28% (7) 0
Glycosuria 30% (11) 4% (1) 0
Combination of tests 14% (5) 52% (13) 9% (4)
Combination of GCT and OGTT
≥ 130 mg/dl 0 8% (2) 16% (7)
≥ 140 mg/dl 0 40% (10) 64% (29)
One-step OGTT
75 g 0 24% (6) 27% (12)
100 g 0 12% (3) 0
GDM: gestational diabetes; FPG: fasting plasma glucose; GCT: 50 g glucose challenge test; OGTT: oral glucose tolerance test.
Benhalima et al. Diabetology & Metabolic Syndrome 2013, 5:66 Page 3 of 7
http://www.dmsjournal.com/content/5/1/66
Coustan criteria were the most commonly used diagnostic
criteria in a two-step approach [Table 2]. Two of the three
university hospitals who participated in the survey, also
used the two-step approach with the Carpenter & Coustan
criteria. When a 75 g OGTT was used, the most com-
monly used diagnostic criteria were the IADPSG criteria
(33%). However, only 11 centers (24%) used the IADPSG
criteria as an one-step strategy since four centers still used
a GCT (three centers with a threshold ≥ 140 mg/dl and
one center with a threshold ≥ 130 mg/dl) before pro-
ceeding to the full OGTT. Estimated prevalences of
GDM were not different between the centers who used
a one-step approach compared to the centers who used
a two-step approach (estimated mean prevalence of 8% ±
2 vs. 7% ± 1, p = 0.519).
Follow up at delivery and postpartum
The protocol concerning the policy at delivery, included
information on monitoring of glycaemia at delivery in
84% of centers and information on the need of an insu-
lin sliding scale in 79% of centers. The protocol also in-
cluded information on the need for an induction in 56%
of centers and it included information on the need for a
caesarean section in 23% of centers. Information con-
cerning neonatal care on the monitoring of blood glu-
cose in newborns was present in 86% of centers and
information on the need for admission on the neonatal
intensive care unit was available in 40% of centers. A
protocol concerning the long term policy for the evalu-
ation of the risk of women with previous GDM to de-
velop T2DM after delivery, was available in 66% of
centers. The most common follow up strategy was
registration of women with GDM in the Flemish project
‘Zoet Zwanger’ (‘Sweet Pregnancy’) in 78% (35) of cen-
ters. This project is an initiative of the Flemish Diabetes
Association and supported by the Flemish government,
whereby women receive yearly remainders to have the
FPG checked by their general practitioner [13]. Monitor-
ing of blood glucose in hospital after the delivery was done
by 47% (21) centers. An universal 75 g OGTT postpartum
was done in 33% (15) of centers and a 75 g OGTT only in
insulin treated women was done in 22% (10) of centers.
Measurement of FPG was done in 13% (6) of centers,
while the measurement of Hba1c was only done in 9% (4)
of centers and self-monitoring of blood glucose at home
was done in only 7% (3) of centers. Of all OGTTs postpar-
tum, the 75 g OGTT was performed less than 6 weeks in
7% of centers, between 6-12 weeks postpartum in 71% of
centers and more than 12 weeks postpartum in 19% of
centers. Women commonly received advice on diet and
weight (91%), on physical activity (86%) and on screening
for T2DM (81%). Advice on the need for preconception
control was given in 52% of centers and advice on the
preferred choice of contraceptives was given in 17% of
centers.
Discussion
This is the first large survey evaluating current practices
on screening for pregestational diabetes in early pregnancy
and GDM in the northern part of Belgium. The debate on
screening for GDM is clearly of concern to the obstetri-
cians, as reflected by the good response rate of nearly 70%
of this survey. The survey is also representative for the
whole region since there was a response rate of more than
50% in every province.
Responders generally believed that it was beneficial to
screen for GDM and that screening for GDM was well or-
ganized in their center. Despite this, our survey demon-
strates that there is a large variation between the different
centers in the northern part of Belgium concerning the
strategy used for screening for GDM. More than half of all
centers screened for GDM before 24 weeks of pregnancy,
mostly based on risk factors. However, many providers
indicated that they did not have one particular screen-
ing test of choice and that different screening tests
could be used. The IADPSG consensus recommends
now that a FPG ≥ 92 mg/dl in early pregnancy can be
classified as GDM [4]. This is however very debated. A
recent evaluation of the FPG in the first prenatal visit to
diagnose GDM in China showed that a FPG between
110-125 mg/dl was a much better predictor of the devel-
opment of GDM and that for their population at least, a
FPG ≥ 92mg/dl at first prenatal visit could not be sup-
ported as the criterion for diagnosis of GDM [14].
To screen for GDM ≥ 24 weeks, more than half of all
centers used the two-step approach with the 100 g OGTT
and Carpenter & Coustan criteria. The most commonly
used cutoff for the GCT in this survey was a threshold
of ≥140 mg/dl. This has shown to identify about 80% of
women with GDM [15]. The yield of the GCT is further
increased to 90% by using a cutoff of ≥130 mg/dl but
Table 2 An overview of the diagnostic criteria of the
OGTT used for GDM before 24 weeks of pregnancy and
for GDM ≥ 24 weeks of pregnancy
Diagnostic criteria GDM< 24 weeks GDM ≥ 24 weeks
(n = 25) (n = 45)
75 g OGTT
Carpenter & Coustan 20% (5) 9% (4)
WHO 0 2% (1)
IADPSG 28% (7) 33% (15)
100 g OGTT
Carpenter & Coustan 48% (12) 52% (23)
NDDG 4% (1) 4% (2)
GDM: gestational diabetes; OGTT: oral glucose tolerance test; WHO: World
Health Association; IADPSG: International Association of Diabetes in Pregnancy
Study Groups; NDDG: National Diabetes Data Group.
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this will inevitably lead to more negative OGTTs. Nearly
one-fourth of all centers implemented the one-step
IADPSG strategy for GDM. However, 4 of the 15 cen-
ters using the IADPSG criteria, used it in a two-step
screening strategy with a GCT. This is probably applied
as a practical solution since in a center with more than
1000 deliveries per year, a one-step approach would lead
to an important increase in workload with the need of
at least 3-4 OGTTs daily. The use of a GCT as a univer-
sal screening tool in a two-step approach with the use
of the IADPSG criteria, is however not yet validated. A
contributing factor to this large variation in practices is
probably the differing recommendations by both inter-
national and local scientific professional organizations.
Various large surveys completed by responders from
many different countries highlight the strong variability
that exists internationally in screening, diagnosis and
management of women with GDM [16-18]. Comparison
between countries is very difficult due to the different
diagnostic strategies and subpopulations. A recent ex-
tensive review on the current screening practices in
Europe shows that screening practice and policy is very
inconsistent across Europe, hampered by lack of con-
sensus and poor clinician awareness of GDM and its
diagnosis [19]. Our survey now shows that practices are
also very variable in one region.
Nearly one third of all centers had a structured data-
base on the number of women with GDM but there are
currently no accurate data on the prevalence of GDM in
Belgium. The Flemish birth register data of 2011 showed
a prevalence of 2.9% of mothers with diabetes, including
both pregestational diabetes as well as GDM [20]. A re-
cent retrospective analysis of the GDM prevalence in the
university hospital of Leuven, showed a GDM prevalence
of 3.3% using the two-step approach [21]. In this survey
the estimated mean prevalence of GDM was 7% but this
was mostly based on crude estimations. This probably
explains the very large variations in GDM prevalence
between the different centers and the absence of a sig-
nificant difference in reported GDM prevalence be-
tween centers using the one-step approach with the
IADPSG criteria compared to centers using a two-step
approach. Many studies have shown an important in-
crease in GDM prevalence when the IADPSG recom-
mendations are implemented [22,23].
In Flanders the mean maternal age at first pregnancy
is now 28 years with 2.3% of women being ≥ 40 years
old at first pregnancy [20]. Moreover, the prevalence of
overweight and obese women continues to increase.
The timely detection of dysglycemia very early in preg-
nancy is therefore essential. Our survey shows that
screening for pregestational diabetes in early pregnancy
was often done based on risk factors and by using a
FPG or random glycaemia as screening tests. It is
generally considered that there is insufficient evidence
to recommend one test over the other. The ADA now
also recommends to screen for undiagnosed T2DM at
the first prenatal visit in those with risk factors using
standard diagnostic criteria for a non-pregnant popula-
tion but does not endorse the recommendation of
IADPSG to classify a FPG ≥ 92 mg/dl in early pregnancy
as GDM [5]. The recent Flemish consensus recom-
mends to screen with a FPG since this has the advan-
tage that it is easy to perform at a low cost [8]. A FPG
has also been shown to diagnose more people than
Hba1c, which in turn is more sensitive than a random
glycaemia [24]. Measurement of Hba1c on the other
hand does not require the patient to fast, which can be
especially challenging for pregnant women. However,
the reference range for Hba1c is lower during preg-
nancy due to a reduced FPG and changes in erythrocyte
turnover. Compared to non-pregnant women, Hba1c is
decreased up to 0.5%, especially in the first and second
trimesters [25].
The best postpartum screening strategy for glucose
intolerance among women with a history of GDM is still
debated. The ADA now recommends to screen women
with a history of GDM at 6-12 weeks postpartum using
the 2-h 75 g OGTT and non-pregnancy diagnostic cri-
teria but this is mostly based on expert consensus or
clinical experience [5]. The most common follow up
strategy in our survey, was registration of women with
GDM in the Flemish project ‘Zoet Zwanger’ (‘Sweet
Pregnancy’). An 75 g OGTT postpartum (universally or
only in insulin treated women) was performed in more
than half of all centers. The estimated risk for women
with previous GDM to develop T2DM in the next 10
years after the index pregnancy, was often underestimated
in our survey. This highlights the need for stronger aware-
ness among obstetricians for the risk of women with
GDM to develop T2DM after pregnancy.
Strengths of this survey are the good response rate
and the detailed questions on screening for pregesta-
tional diabetes in early pregnancy, on screening for
GDM both before and ≥ 24 weeks of pregnancy and on
the follow-up strategy postpartum. Since the aim was
to obtain one survey per obstetrical center, it cannot be
excluded that within one center different screening
strategies are used by different providers. However, we
feel that this survey is representative since most cen-
ters had a written protocol regarding the policy for
GDM.
In conclusion, despite the fact that responders gener-
ally believed that it was beneficial to screen for GDM,
this survey demonstrates that there is a large variation
between the different centers in the northern part of
Belgium concerning the strategy used for screening for
pregestational diabetes in early pregnancy and screening
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for GDM. Only one-fourth of centers have imple-
mented the one-step IADPSG screening strategy. A
contributing factor to this large variation in practices is
probably the differing recommendations by both inter-
national and local scientific professional organizations.
More research is necessary to investigate the most ap-
propriate screening strategy for pregestational diabetes
in early pregnancy and to search for the most cost
effective screening strategy for GDM in our population.
The development of an uniform and cost effective
screening strategy in Belgium, will allow more women
during pregnancy to timely receive treatment with glucose-
lowering therapy to improve obstetrical outcomes and
this will also allow for a more timely detection of T2DM
after pregnancy.
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